Cadila Healthcare
-
{
- All
- News
- Videos
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
South Korea's Enzychem To Make Cadila's COVID-19 Shot
South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday.
-
This Company Will Produce Pharma Firm Cadila's 3-Dose COVID-19 Vaccine 'ZyCov-D'
Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.
-
Cadila Healthcare Starts Producing COVID-19 Vaccine Candidate
Cadila Healthcare has started producing its potential COVID-19 vaccine for which it will seek emergency use authorisation in May or June, its managing director told Reuters, with an aim to make up to 240 million doses a year.
-
Cadila Seeks Nod To Repurpose Hepatitis C Drug For Covid Treatment
Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
-
Phase 1 Trials Of 2 Covid Vaccines Reveal "Excellent Safety": Minister
Phase-I clinical trials have revealed "excellent safety" of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with ICMR and Cadila Healthcare Ltd and their immunogenicity testing is now in progress, Minister of State for Health Ashwini Choubey informed the Rajya Sabha on Tuesday.
-
Zydus Cadila Gets USFDA Nod To Drug That Treats Severe Acne Vulgaris
Zydus Pharmaceuticals has received the final approval from the USFDA to market Minocycline Hydrochloride Extended Release Tablets
-
Cadila Gets USFDA's Final Nod To Market Ethacrynate Sodium
Cadila Healthcare shares trade (at 11.55 am) at Rs 450.50, 0.93% higher than the previous session's closing on BSE
-
Billionaire Father, Son Turn 10-Storey Mumbai Office Into World Beater
Cadila's stock delivered returns of almost 50 percent, making it the best among generic drugmakers worldwide with a market value of more than $1 billion.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
South Korea's Enzychem To Make Cadila's COVID-19 Shot
South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday.
-
This Company Will Produce Pharma Firm Cadila's 3-Dose COVID-19 Vaccine 'ZyCov-D'
Drugmaker Shilpa Medicare Limited said on Friday it had agreed to produce Cadila Healthcare Ltd's three-dose COVID-19 vaccine.
-
Cadila Healthcare Starts Producing COVID-19 Vaccine Candidate
Cadila Healthcare has started producing its potential COVID-19 vaccine for which it will seek emergency use authorisation in May or June, its managing director told Reuters, with an aim to make up to 240 million doses a year.
-
Cadila Seeks Nod To Repurpose Hepatitis C Drug For Covid Treatment
Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
-
Phase 1 Trials Of 2 Covid Vaccines Reveal "Excellent Safety": Minister
Phase-I clinical trials have revealed "excellent safety" of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with ICMR and Cadila Healthcare Ltd and their immunogenicity testing is now in progress, Minister of State for Health Ashwini Choubey informed the Rajya Sabha on Tuesday.
-
Zydus Cadila Gets USFDA Nod To Drug That Treats Severe Acne Vulgaris
Zydus Pharmaceuticals has received the final approval from the USFDA to market Minocycline Hydrochloride Extended Release Tablets
-
Cadila Gets USFDA's Final Nod To Market Ethacrynate Sodium
Cadila Healthcare shares trade (at 11.55 am) at Rs 450.50, 0.93% higher than the previous session's closing on BSE
-
Billionaire Father, Son Turn 10-Storey Mumbai Office Into World Beater
Cadila's stock delivered returns of almost 50 percent, making it the best among generic drugmakers worldwide with a market value of more than $1 billion.
